← Back to patent-cliff list
NMBS-2
Tier C — Watch / tradeNMBS-2
Nimbus Therapeutics LLC
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：MAP4K1
Indications (approved)：Non-small cell lung cancer, Renal cell carcinoma, Solid tumour, 食管胃结合部肿瘤, Gastric cancer, Neoplasm
Regional status
US
Phase II
2021-11-05
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of NMBS-2?
Approved indications include: Non-small cell lung cancer, Renal cell carcinoma, Solid tumour, 食管胃结合部肿瘤, Gastric cancer, Neoplasm.
When does the NMBS-2 patent expire?
No public expiry year is available for NMBS-2 yet; this page updates once verified.
How do I get a quote for NMBS-2 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21